Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1 beta and sCD200 in cases of Samter's syndrome: 36 months follow-up

Yalcin A. D., Ucar S., GÜMÜŞLÜ S., Strauss L. G.

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, vol.35, no.4, pp.524-527, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 4
  • Publication Date: 2013
  • Doi Number: 10.3109/08923973.2013.811598
  • Journal Name: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.524-527
  • Keywords: Anti-IgE, aspirin-induced asthmatic patients, eosinophil cationic peptide, fractional exhale nitric oxide concentrations, 25-hydroxyvitamin-D, IL-1 beta, omalizumab, Samter's syndrome, soluble CD200, ENDOSCOPIC SINUS SURGERY, ALLERGIC-ASTHMA, NASAL POLYPS, ANTI-IGE, TRIAD
  • Dokuz Eylül University Affiliated: Yes

Abstract

Contex: The historic triad of nasal polyposis, asthma and intolerance to aspirin and related chemicals, recently designated as Samter's syndrome, is an inflammatory condition of unknown pathogenesis. This study surveyed the levels of chosen serum eosinophil cationic peptide (ECP), soluble CD200 (SCD200), interleukin (IL)-1 beta, high sensitive C-reactive protein (hs-CRP) and 25-hydroxyvitamin-D (25(OH)D) in the aspirin-induced asthmatic patients treated with anti-IgE therapy to investigate their roles in the pathogenesis of disease perpetuation and anti-IgE therapy's impact on them.